NEKTAR THERAPEUTICS 4
4 · NEKTAR THERAPEUTICS · Filed Feb 7, 2014
Insider Transaction Report
Form 4
Medve Robert
Chief Medical Officer
Transactions
- Award
Stock Option
2014-02-05+12,500→ 12,500 totalExercise: $12.43Exp: 2022-02-04→ Common Stock (12,500 underlying) - Award
Stock Option
2014-02-05+12,500→ 12,500 totalExercise: $12.43Exp: 2022-02-04→ Common Stock (12,500 underlying)
Footnotes (2)
- [F1]This option was granted on February 5, 2014 and vests in monthly installments over the four-year period following the grant date.
- [F2]This stock option is subject to both time-based vesting and performance-based vesting conditions, both of which must be met before the shares subject to the option become vested and exerciseable. The time-based vesting is on a monthly pro-rata basis over a period of four (4) years from the grant date (February 5, 2014). The performance-based vesting condition will be met only if Nektar (or a licensee) files, within five years following the grant date, a new drug registration with the FDA or the European Medicines Agency for a significant drug candidate program (avg. royalty >7.5%) including, without limitation, the following: (1) etirinotecan pegol; (2) NKTR-061/Amikacin Inhale; (3) BAX-855 (a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein; or (4) dry powder inhaled ciprofloxacin.